Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7868181 | 0.90 | CCR3 (0.51) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL4237159 | 0.88 | S1PR1 (0.47) | DRD2DRD4DRD3S1PR1S1PR5 | |
| SCHEMBL1588025 | 0.87 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL5242533 | 0.85 | SLC6A4 (0.53) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL6263887 | 0.85 | SIGMAR1 (0.52) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL5230749 | 0.84 | SIGMAR1 (0.44) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL13596992 | 0.84 | SIGMAR1 (0.44) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| Hydrochloric Acid SCHEMBL23882203 | 0.83 | DRD2 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL325460 | 0.83 | SIGMAR1 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL23063982 | 0.83 | SIGMAR1 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| EP-2785715-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| US-5554752-A | SPIRO FUSED PIPERIDINES CAPABLE OF BINDING TO A VESAMICOL RECEPTOR AND HAVING ANTICHOLINERGIC PROPERTIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-09-10 | — | — | US | disclosed |
| US-5457207-A | Anticholinergic agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1995009631-A1 | SPIROVESAMICOLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-04-13 | — | — | WO | disclosed |
| US-4169200-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | F12, FAR1, NQO2 | SIGMAR1 1878/4885DRD2 2785/4885HTR1A 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.